ArticleInternational journal of colorectal disease2026
The subtype identification of colorectal cancer and construction of the risk model based on cholesterol synthesis-related genes to predict prognosis and guide immunotherapy.
Article in International journal of colorectal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interplay Between Gut Microbiota and Cholesterol Metabolism in Colorectal Cancer.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a common malignant tumor worldwide. The cholesterol synthesis (CS) pathway is crucial in the occurrence and development of cancer. This study aims to predict the prognosis of CRC patients based on the cholesterol synthesis-related genes (CSRGs).
methodsThe patient data of CRC were downloaded from the TCGA and GEO databases, and the CSRGs were downloaded from Genecards. In the TCGA-CRC training set, univariate Cox regression analysis was conducted on the CSRGs, and subtype classification was performed through consensus clustering. Combined with the PPI network and regression analysis, key CSRGs were identified to establish a prognostic model. ROC curves and Kaplan-Meier survival analysis were used to evaluate the model and validate it in the GSE17538 validation set. At the same time, immune analysis and drug sensitivity analysis were conducted. Finally, the functions of these characteristic genes were investigated in an in vitro cell model.
resultsThe TCGA-CRC was divided into two subtypes. A 10-gene Cholesterol Synthesis-related Risk Signature (CSRS) was constructed. The patients were grouped according to the median value of the CSRS. The high-CSRS group had a poorer prognosis, and the abundance of macrophages, neutrophils, and TIL was higher in this group. The drug sensitivity prediction indicated that several candidate drugs (such as Linsitinib) might affect the progression of CRC through unique mechanisms. In vitro experiments demonstrated that EEF1A2 could promote the malignant progression of tumors.
conclusionThe results of this project provide some guidance for elucidating potential CS-related biomarkers for predicting prognosis in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.